How Much Longer Will This Company Be Around?

Quote
Well the third qtr just finished. Did angiosculpt close their doors as the previous poster predicted? Also, just heard IDEV has lost several reps over just the last couple of weeks. I guess the wheels are finally starting to fall off.
 












Good catch. I misread the post and thought it said angiosculpt. Needless to say, it looks like IDEV is experiencing a lot of turnover lately. Can't understand what is keeping them afloat.
 






IDEV braided stent is nothing more than Wallstent II.. but worse.. acts like a cheese cutter, aka plaque downstream.. foreshortening.. delivery problems.. these are all issues industry dealt with 10 years ago.. this troll of a company is a throwback without a clue. They've approached several experienced catheter/stent engineers who told IDev they're trying to perfect 1990s technology.. and that they've got no interest in going backwards.
 


















Has anyone heard what the data/patency rates looks like from IDev's Superb Trial? They're supposedly presenting it in October at VIVA, but some of their reps are already talking serious smack. They're telling Doc's that their SFA data is phenomenal and far superior to any other stent, including DES.
 






IDEV can talk all the smack they want, they've lost what little market share they had. They've lost most of their top reps, and only promoted those who would buy large blocks of stock. Two words for IDEV................tick tock.
 












How many of the investigators in the trial own Idev stock?
How many of the investigators in the trial are Proctors for an Idev hands on training course?
Hmmmm. Makes u wonder if the data is legit.?
 






IDEV is a privately held company and without a peripheral indication they are not able to proctor training courses. The data I think your referring to is being presented at VIVA which comes from 40 different sites and has 250 plus patients so I doubt the data is cooked. If the data is as good as the patency data from Leipzig Supera should get their indication very soon. Once they receive indication they are primed to be bought.
 




































I think IDev will be presenting their Superb data today or tomorrow at VIVA. My prediction is roughly 80% patency at 12 months with a 75mm mean lesion length. Anything less and they're toast, but much like the LifeStent, the only reason their patency rates will exceed the average BMS rates is because their study lacks complex "real world" lesions.
 
























Top Bottom
Back
Quote